This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Jazz Pharmaceuticals" – news · newspapers · books · scholar · JSTOR(July 2018) (Learn how and when to remove this message)
This article contains content that is written like an advertisement. Please help improve it by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view.(July 2018) (Learn how and when to remove this message)
(Learn how and when to remove this message)
Jazz Pharmaceuticals plc
Company type
Public
Traded as
Nasdaq: JAZZ
S&P 400 component
Industry
Biotechnology
Pharmaceutical
Predecessor
Jazz Pharmaceuticals, Inc. (before the 2012 tax inversion to Ireland)
Founded
2003; 21 years ago (2003) in California, U.S.
Headquarters
Dublin, Ireland
Area served
Worldwide
Key people
Bruce C. Cozadd (chairman and CEO)
Products
Pharmaceutical drugs
Brands
Xyrem
Erwinaze
Defitelio
FazaClo
FazaClo HD
Luvox CR
Prialt
Vyxeos
Revenue
US$3.83 billion (2023)
Operating income
US$579 million (2023)
Net income
US$415 million (2023)
Total assets
US$11.4 billion (2023)
Total equity
US$3.74 billion (2023)
Number of employees
c. 2,800 (2023)
Website
jazzpharma.com
Footnotes / references [1]
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States.[2] One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales.[1] In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.[3]
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.[4]
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[5]
^ ab"Jazz Pharmaceuticals PLC 2023 Annual Report (Form 10-K)". sec.gov. U.S. Securities and Exchange Commission. 28 February 2024. Retrieved 28 February 2024.
^"History". Jazz Pharmaceuticals. Archived from the original on 23 November 2016. Retrieved 22 November 2016.
^"Axsome To Buy Sunosi From Jazz". NASDAQ. Retrieved 28 March 2022.
^"Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in "Off-label" Marketing Investigation". Archived from the original on 2021-07-20. Retrieved 2016-06-08.
^"Teva wins controversial PhRMA bid despite protests from branded rivals". 18 July 2016. Archived from the original on 19 July 2016. Retrieved 18 July 2016.
and 26 Related for: Jazz Pharmaceuticals information
JazzPharmaceuticals plc (a merger of JazzPharmaceuticals, Inc. and Azur Pharma plc) is a global biopharmaceutical company with a focus on oncology and...
and Drug Administration in 2018. It is a subsidiary of JazzPharmaceuticals. GW Pharmaceuticals was founded in 1998 by doctors Geoffrey Guy and Brian Whittle...
in JazzPharmaceuticals filing patent infringement cases against them. Hikma Pharmaceuticals had been the first company to file an ANDA and Jazz Pharmaceuticals...
system (CNS) depressant and it is taken by mouth. Manufactured by the JazzPharmaceuticals company, it was approved for medical use in the United States in...
narcolepsy before selling the license to solriamfetol to Jazz in 2014; JazzPharmaceuticals paid Aerial $125 million up front and will pay Aerial and...
transplant in 2013; Gentium had developed it. At the end of that year, JazzPharmaceuticals acquired Gentium. In March 2016, the U.S. Food and Drug Administration...
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through...
www.icd10data.com. "Epocrates – Adderall". Retrieved 2013-07-19. "JazzPharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive...
Global Information
US$3.83 billion (2023)